Table 1. Results of current studies on SBRT for liver metastases (including breast cancer origin).
| Reference | Study year | Number of patients [lesions] | BCLM patients | Tumor volume (median, cm3) | Follow up (median, months) | RT dose (Gy/Fr) | Toxicity (Grade 3/≥4) | Survival | Local control (% or median) |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Median, months | % | |||||||||
| Wulf et al. (59) | 2006 | 39 [51] | 11 | NA (CTVmin 9/max 355) | 15 [2–85] | 26–37.5 Gy/1–3 Fr | 0/0 | 72/32 (1 y/2 y) | 92/66 (1 y/2 y) | |
| Lee et al. (52) | 2009 | 68 [143] | 12 | 75.9 | 10.8 | 41.4 (27.7–60) Gy/6 Fr | Acute: 6 (9%)/1 (1%), late: 0/0 | 17.6 | 79 (1 y) | 71 (1 y) |
| Rusthoven (47) | 2009 | 48 [63] | NA (diameter 2.7 cm) | 16 | 36–60 Gy/3Fr | G3 1 (2%) | 20.5 | 92/95 (1 y/2 y) | ||
| Fumagalli et al. (54) | 2012 | 90 [139] | 8 | 28 | 17 | 27–60 Gy/3–6 Fr | 0/0 | 70.0 (2 y) | 84.5/66.1 (1 y/2 y) | |
| Yuan et al. (44) | 2014 | 57 [80] | 7 | 27.6 | 20.5 | 39–54 Gy/3–7 Fr | 0/0 | 37.5 | 89.6/72.2 (1 y/2 y) | 94.4/89.7 (1 y/2 y) |
| Yamashita et al. (49) | 2014 | 51 | 3 | 26 | 475.5 days | 30–60 Gy/3–8 Fr | 0/0 | 71.9 (2 y) | 64.2 (2 y) | |
| Scorsetti et al. (55) | 2016 | 33 [43] | 33 (100%) | 20 | 24 | 48–57 Gy/3–4 Fr | 0/0 | 48 | 93/66 (1 y/2 y) | 98/90 (1 y/2 y) |
| Onal et al. (60) | 2018 | 22 [29] | 22 (100%) | 16 | 54 Gy/3 Fr | NA/0 | 85/57 (1 y/2 y) | 100/88 (1 y/2 y) | ||
| Mahadevan et al. (61) | 2018 | 427 [568] | 42 | 40 | 14 | 45 [12–60] Gy/3 Fr | 0/0 | 22 | 52 months (median) | |
SBRT, stereotactic body radiation therapy; BCLM, breast cancer liver metastases; Gy, gray; Fr, fractions; NA, non applicable; y, years.